APA (7th ed.) Citation

C, O., H, I., S, P., L, S., G, D., WP, B., . . . JE, R. (2013). Gemtuzumab ozogamicin can reduce minimal residual disease in patients with childhood acute myeloid leukemia. Cancer, 119(22), 4036. https://doi.org/10.1002/cncr.28334

Chicago Style (17th ed.) Citation

C, O'Hear, et al. "Gemtuzumab Ozogamicin Can Reduce Minimal Residual Disease in Patients with Childhood Acute Myeloid Leukemia." Cancer 119, no. 22 (2013): 4036. https://doi.org/10.1002/cncr.28334.

MLA (9th ed.) Citation

C, O'Hear, et al. "Gemtuzumab Ozogamicin Can Reduce Minimal Residual Disease in Patients with Childhood Acute Myeloid Leukemia." Cancer, vol. 119, no. 22, 2013, p. 4036, https://doi.org/10.1002/cncr.28334.